NTLA
USDIntellia Therapeutics Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$8.200
最高
$8.445
最低
$8.060
交易量
9.93M
公司基本面
市值
864.9M
行業
生物科技
國家
United States
交易統計
平均交易量
4.19M
交易所
NGM
貨幣
USD
52週範圍
相關新聞
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics with a Buy and lowers the price target from $74 to $54.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $10 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $10 price target.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline,
相關股票
TOST
Toast Inc.
HBANM
Huntington Bancshares Incorporated Depositary Shares each representing a 1/1000th interest in a share of Huntington Series I Preferred Stock
RCS
PIMCO Strategic Income Fund Inc.
VCNX
Vaccinex Inc.
FLNC
Fluence Energy Inc.
保持更新
設定價格提醒，獲取AI分析更新和即時市場新聞。